Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Redefining Respiratory Endpoints: Inside Strados Labs’ Vision for Objective, Real-World Lung Monitoring 
Shots:  Clinical trial sponsors are rapidly moving toward objective, continuous respiratory monitoring, adopting technologies like the RESP Biosensor to improve endpoint sensitivity, safety assessments, and real-world patient insight.  Beyond cough frequency, emerging acoustic biomarkers, such as wheezes, crackles, cough intensity, and cough bout patterns, are redefining how respiratory function and therapeutic impact are measured in modern trials.  PharmaShots welcomes Nick Delmonico,…
December 15, 2025
A New Era for Myeloma Patients: Regeneron’s Karen Rodriguez Lorenc on Lynozyfic’s Rising Global Impact 
Shots:  Lynozyfic is emerging as a standout in heavily pre-treated multiple myeloma. In the pivotal LINKER-MM1 trial, it delivered early, deep, and durable responses, offering renewed hope for patients with limited options. Its response-adapted dosing regimen further reduces treatment burden and enhances convenience  Regeneron is accelerating progress with a broad development strategy, advancing Lynozyfic across multiple therapy lines, combination regimens, precursor conditions, and global markets. The program…
December 8, 2025
Evorpacept’s Momentum in HER2+ Gastric Cancer: A Conversation with Jason Lettmann from ALX Oncology 
Shots:  Evorpacept emerges as the only CD47-blocking therapy with strong clinical activity and a highly manageable safety profile, thanks to its unique inactive Fc design that enables targeted tumor destruction while sparing healthy cells  Updated ASPEN-06 data highlights CD47 overexpression as a powerful predictive biomarker, showing dramatic improvements in ORR, DOR, PFS, and OS for patients with…
December 3, 2025
Inside Sapient’s Multi-Omics Revolution: A Deep Dive with Founder Mo Jain 
Shots:    Sapient’s new partnership with Alamar Biosciences supercharges its multi-omics engine, bringing the ultra-sensitive NULISA™ platform in-house to capture hard-to-measure cytokines and chemokines, unlocking deeper biological insights beyond the reach of mass spectrometry alone  The collaboration with Rancho Biosciences is redefining large-scale data intelligence, enabling Sapient’s DynamiQ™ platform to seamlessly integrate, structure, and analyze massive multi-omics and real-world…
December 1, 2025
Tariffs, Compliance, and the Future of Drug Pricing: A Conversation with Jesse Mendelsohn from Model N 
Shots:    U.S. tariff shifts are forcing pharma manufacturers to accelerate reshoring, reduce duty exposure, and stabilize pricing, fueling renewed investment in onshore final manufacturing, Most Favored Nation pricing strategies, and selective direct-to-consumer pilots to secure tariff relief amid policy volatility  As pricing, reimbursement, market access, and trade regulations evolve, companies are prioritizing late-stage, lower-risk…
November 24, 2025
Inside neffy’s Launch Strategy: A Stimulating Conversation with Richard Lowenthal, CEO & Co-Founder of ARS Pharmaceuticals 
Shots:  Inconsistent access to epinephrine auto-injectors continues to be a major unmet need in the management of anaphylaxis  neffy, an innovative intranasal epinephrine spray, provides a needle-free alternative for the emergency treatment of severe allergic reactions, including anaphylaxis, in adults and children aged four years and older who weigh at least 33 lbs  Richard Lowenthal,…
November 3, 2025
Optimizing Life Sciences CRM: A Candid Conversation with Akshay Kapadia from Conexus Solutions 
Shots:  As life sciences organizations increasingly adopt integrated data, AI, and advanced analytics, CRM platforms are becoming powerful tools to anticipate customer needs, personalize engagements, and measure impact in real-time across multiple channels    In the coming years, CRM will transform into a strategic intelligence hub, empowering teams to make data-driven decisions and helping companies…
October 27, 2025
Enhancing R&D Prowess in Oncology: Denis R. Beckford-Vera from Champions Oncology in Conversation with PharmaShots 
Shots:  The complexity of human physiology continues to challenge drug development, as conventional models often fail to provide critical insights, resulting in high attrition rates  Champions Oncology bridges this gap through patient-derived xenograft and ex vivo platforms built from real tumors, integrated with radiolabeled compounds for deeper R&D insights  Denis R. Beckford-Vera, Head of Radiopharmacology…
October 13, 2025
Breaking New Ground in Oncology: Leonard Mazur from Citius Pharmaceuticals in Conversation with PharmaShots 
Shots:   Citius Pharmaceuticals celebrates its first-ever FDA approval with Lymphir, a novel therapy for relapsed or refractory cutaneous T-cell lymphoma     In an exclusive conversation, Leonard Mazur, Co-Founder and CEO at Citius Pharmaceuticals, shares insights on Lymphir’s launch strategy and its potential impact on the oncology landscape    Leonard also highlights Mino-Lok, Citius’ innovative…
October 6, 2025
Load more